Neurospecific Proteins as Transdiagnostic Markers of Affective Disorders


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Mental disorders have many differences in pathogenesis and clinical symptoms, however, they are characterized by general neurobiological processes that occur with a damage of nervous tissue, disturbance of blood-brain barrier, inclusion of autoimmune mechanisms, neurodegenerative processes and release of neurospecific proteins into the liquor and into the blood. We presented a review of current literature devoted to studies of the role of neurospecific proteins in the pathogenesis of affective disorders. Glial fibrillar acidic protein (GFAP), S-100 protein, myelin basic protein (MBP), and neuron specific enolase (NSE) reflect damage of neurons, astrocytes and oligodendrocytes in depressive disorders and they could be considered as transdiagnostic nonspecific markers of affective disorders.

About the authors

L. A. Levchuk

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Email: nchjournal@gmail.com
Russia, Tomsk

N. A. Bokhan

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Email: nchjournal@gmail.com
Russia, Tomsk

S. A. Ivanova

Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Email: nchjournal@gmail.com
Russia, Tomsk

References

  1. Maiolo L., Guarino V., Saracino E., Convertino A., Melucci M., Muccini M., Ambrosio L., Zamboni R., Benfenati V. // Adv. Healthc. Mater. 2021. V. 10. № 1. e2001268. https://doi.org/10.1002/adhm.202001268
  2. Mayegowda S.B., Thomas C. // J. Basic Clin. Physiol. Pharmacol. 2019. V. 30. № 4. https://doi.org/10.1515/jbcpp-2018-0120
  3. Franke H., Illes P. // Neurosci. Lett. 2014. V. 565. P. 14–22. https://doi.org/10.1016/j.neulet.2013.09.056
  4. Kaul D., Schwab S.G., Mechawar N., Matosin N. // Neurosci. Biobehav. Rev. 2021. V. 124. P. 193–215. https://doi.org/10.1016/j.neubiorev.2021.01.025
  5. Keshavarz M. // Acta Neuropsychiatr. 2017. V. 29. № 3. P. 140–152. https://doi.org/10.1017/neu.2016.56
  6. Rajkowska G., Miguel-Hidalgo J.J. // Methods Mol. Biol. 2019. V. 1938. P. 247–254. https://doi.org/10.1007/978-1-4939-9068-9_17
  7. Wang J., Qin J., Wang P., Sun Y., Zhang Q. // Mediators Inflamm. 2020. V. 2020, Article ID 3497920. https://doi.org/10.1155/2020/3497920
  8. Gules E., Iosifescu D.V., Tural U. // Neuropsychobiology. 2020. V. 79. № 3. P. 214–221. https://doi.org/10.1159/000505782
  9. Karabulut S., Taşdemir I., Akcan U., Kucukali C.I., Tuzun E., Çakır S. // Turk. Psikiyatri Derg. 2019. V. 30. № 2. P. 75–81.
  10. Block M.L., Hong J.S. // Prog. Neurobiol. 2005. V. 76. № 2. P.77–98. https://doi.org/10.1016/j.pneurobio.2005.06.004
  11. Zavorotnyy M., Zollner R., Schulte-Gustenberg L.R., Wulff L., Schoning S., Dannlowski U., Kugel H., Arolt V., Konrad C. // J. Neural. Transm. (Vienna). 2018. V. 125. № 2. P. 229–238. https://doi.org/10.1007/s00702-017-1811-y
  12. Lotrich F.E., Butters M.A., Aizenstein H., Marron M.M., Reynolds C.F. 3rd, Gildengers A.G. // Int. J. Geriatr. Psychiatry. 2014. V. 29. № 6. P. 635–44. https://doi.org/10.1002/gps.4048
  13. Losenkov I.S., Mulder N.J.V., Levchuk L.A., Vyalova N.M., Loonen A.J.M., Bosker F.J., Simutkin G.G., Boiko A.S., Bokhan N.A., Wilffert B., Hak E., Schmidt A.F., Ivanova S.A. // Front. Psychiatry. 2020. V. 11. P. 38. https://doi.org/10.3389/fpsyt.2020.00038
  14. Erickson E.K., Grantham E.K., Warden A.S., Harris R.A. // Pharmacol. Biochem. Behav. 2019. V. 177. P. 34–60. https://doi.org/10.1016/j.pbb.2018.12.007
  15. Kruyer A., Kalivas P.W., Scofield M.D. // Neuropsychopharmacology. 2022. Epub ahead of printhttps://doi.org/10.1038/s41386-022-01338-w
  16. Wang Q., Jie W., Liu J.H., Yang J.M., Gao T.M. // Glia. 2017. V. 65. № 8. P. 1227–1250. https://doi.org/10.1002/glia.23143
  17. Schroeter M.L., Sacher J., Steiner J., Schoenknecht P., Mueller K. // Curr. Drug Targets. 2013. V. 14. № 11. P. 1237–1248. https://doi.org/10.2174/13894501113149990014
  18. Giovannoni F., Quintana F.J. // Trends Immunol. 2020. V. 41. № 9. P. 805–819. https://doi.org/10.1016/j.it.2020.07.007
  19. Gulyaeva N.V. // J. Neurochem. 2015. V. 132. № 3. P. 263–265. https://doi.org/10.1111/jnc.13016
  20. Sofroniew M.V. // Trends Immunol. 2020. V. 41. № 9. P. 758–770. https://doi.org/10.1016/j.it.2020.07.004
  21. Miguel-Hidalgo J.J., Waltzer R., Whittom A.A., Austin M.C., Rajkowska G., Stockmeier C.A. // J. Affect. Disord. 2010. V. 127. Issue 1–3. P. 230–240. https://doi.org/10.1016/j.jad.2010.06.003
  22. Kim R., Healey K.L., Sepulveda-Orengo M.T., Reissner K.J. // Prog. Neuropsychopharmacol. Biol. Psychiatry. 2018. V. 87. Pt A. P. 126–146. https://doi.org/10.1016/j.pnpbp.2017.10.002
  23. Qi X.R., Kamphuis W., Shan L. // Front. Cell Neurosci. 2019. V. 13. P. 503. https://doi.org/10.3389/fncel.2019.00503
  24. Steinacker P., Al Shweiki M.R., Oeckl P., Graf H., Ludolph A.C., Schonfeldt-Lecuona C., Otto M. // J. Psychiatr. Res. 2021. V. 144. P. 54–58. https://doi.org/10.1016/j.jpsychires.2021.09.012
  25. Donato R., Cannon B.R., Sorci G., Riuzzi F., Hsu K., Weber D.J., Geczy C.L. // Curr. Mol. Med. 2013. V. 13. № 1. P. 24–57.
  26. Baecker J., Wartchow K., Sehm T., Ghoochani A., Buchfelder M., Kleindienst A. // J. Neurotrauma. 2020. V. 37. № 8. P. 1097–1107. https://doi.org/10.1089/neu.2019.6475
  27. Bartoli F., Misiak B., Crocamo C., Carra G. // Prog. Neuropsychopharmacol. Biol. Psychiatry. 2020. V. 101. P. 109922. https://doi.org/10.1016/j.pnpbp.2020.109922
  28. Ceschi M.A., da Costa J.S., Lopes J., Câmara V.S., Campo L.F., Borges A., Goncalves C., de Souza D.F., Konrath E.L., Karl A., Guedes I.A., Dardenne L.E. // Eur. J. Med. Chem. 2016. V. 121. P. 758–772. https://doi.org/10.1016/j.ejmech.2016.06.025
  29. Michetti F., D’Ambrosi N., Toesca A., Puglisi M.A., Serrano A., Marchese E., Corvino V., Geloso M.C. // J. Neurochem. 2019. V. 148. № 2. P. 168–187. https://doi.org/10.1111/jnc.14574
  30. Zhang L., Verwer R.W.H., Zhao J., Huitinga I., Lucassen P.J., Swaab D.F. // J. Affect. Disord. 2021. V. 295. P. 893–903. https://doi.org/10.1016/j.jad.2021.08.098
  31. Kroksmark H., Vinberg M. // Nord. J. Psychiatry. 2018. V. 72. № 7. P. 462–470. https://doi.org/10.1080/08039488.2018.1472295
  32. Tural U., Irvin M.K., Iosifescu D.V. // World J. Biol. Psychiatry. 2021. V. 15. P. 1–8. https://doi.org/10.1080/15622975.2021.2013042
  33. Navines R., Oriolo G., Horrillo I., Cavero M., Aouizerate B., Schaefer M., Capuron L., Meana J.J., Martin-Santos R. // Int. J. Neuropsychopharmacol. 2022. V. 25. № 6. P. 468–478. https://doi.org/10.1093/ijnp/pyac016
  34. Andreazza A.C., Cassini C., Rosa A.R., Leite M.C., de Almeida L.M., Nardin P., Cunha A.B., Cereser K.M., Santin A., Gottfried C., Salvador M., Kapczinski F., Goncalves C.A. // J. Psychiatr. Res. 2007. V. 41. № 6. P. 523–529. https://doi.org/10.1016/j.jpsychires.2006.07.013
  35. Machado-Vieira R., Lara D.R., Portela L.V., Goncalves C.A., Soares J.C., Kapczinski F., Souza D.O. // Eur. Neuropsychopharmacol. 2002. V. 12. № 3. P. 269–272. https://doi.org/10.1016/s0924-977x(02)00029-9
  36. Salzer J.L., Zalc B. // Curr. Biol. 2016. V. 26. № 20. R971–R975. https://doi.org/10.1016/j.cub.2016.07.074
  37. Harauz G., Ladizhansky V., Boggs J.M. // Biochemistry. 2009. V. 48. № 34. P. 8094–104. https://doi.org/10.1021/bi901005f
  38. English J.A., Pennington K., Dunn M.J., Cotter D.R. // Biol. Psychiatry. 2011. V. 69. № 2. P. 163–172. https://doi.org/10.1016/j.biopsych.2010.06.031
  39. Williams M.R., Sharma P., Macdonald C., Pearce R.K.B., Hirsch S.R., Maier M. // Eur. Arch. Psychiatry. Clin. Neurosci. 2019. V. 269. № 4. P. 387–395. https://doi.org/10.1007/s00406-018-0904-4
  40. Valdes-Tovar M., Rodriguez-Ramirez A.M., Rodriguez-Cardenas L., Sotelo-Ramirez C.E., Camarena B., Sanabrais-Jimenez M.A., Solis-Chagoyan H., Argueta J., Lopez-Riquelme G.O. // World J. Psychiatry. 2022. V. 12. № 2. P. 264–285. https://doi.org/10.5498/wjp.v12.i2.264
  41. Schmitt A., Simons M., Cantuti-Castelvetri L., Falkai P. // Eur. Arch. Psychiatry Clin. Neurosci. 2019. V. 269. № 4. P. 371–372. https://doi.org/10.1007/s00406-019-01019-8
  42. Jakobsson J., Bjerke M., Ekman C.J., Sellgren C., Johansson A.G., Zetterberg H., Blennow K., Landen M. // Neuropsychopharmacology. 2014. V. 39. № 10. P. 2349–2356. https://doi.org/10.1038/npp.2014.81
  43. Levchuk L.A., Roshchina O.V., Simutkin G.G., Bokhan N.A., Ivanova S.A. // Neurochemical Journal. 2021. V. 15. № 1. P. 86–90. https://doi.org/10.1134/S1819712421010074
  44. Schmidt F.M., Mergl R., Stach B., Jahn I., Schonknecht P. // World J. Biol. Psychiatry. 2015. V. 16. P. 106–113. https://doi.org/10.3109/15622975.2014.952776
  45. Isgro M.A., Bottoni P., Scatena R. // Adv. Exp. Med. Biol. 2015. V. 867. P. 125–143. https://doi.org/10.1007/978-94-017-7215-0_9
  46. Streitburger D.P., Arelin K., Kratzsch J., Thiery J., Steiner J., Villringer A., Mueller K., Schroeter M.L. // PLoS One. 2012. V. 7. № 8. e43284. https://doi.org/10.1371/journal.pone.0043284
  47. Shi X.F., Kondo D.G., Sung Y.H., Hellem T.L., Fiedler K.K., Jeong E.K., Huber R.S., Renshaw P.F. // Bipolar Disord. 2012. V. 14. № 6. P. 607–617. https://doi.org/10.1111/j.1399-5618.2012.01040.x
  48. Eyre H., Baune B.T. // Psychoneuroendocrinology. 2012. V. 37. № 9. P. 1397–1416. https://doi.org/10.1016/j.psyneuen.2012.03.019

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Л.А. Левчук, Н.А. Бохан, С.А. Иванова